Voloridge Investment Management
NTLA icon

Voloridge Investment Management’s Intellia Therapeutics NTLA Stock Holding History

Voloridge Investment Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35M Buy
2,066,356
+454,822
+28% +$6.37M 0.15% 220
2026
Q1 		$20.7M Sell
1,611,534
-125,916
-7% -$1.6M 0.08% 331
2025
Q4 		$15.6M Buy
1,737,450
+127,245
+8% +$1.75M 0.05% 438
2025
Q3 		$27.8M Buy
1,610,205
+56,971
+4% +$702K 0.09% 262
2025
Q2 		$14.6M Buy
1,553,234
+37,620
+2% +$309K 0.05% 424
2025
Q1 		$10.8M Sell
1,515,614
-11,380
-0.7% -$115K 0.04% 551
2024
Q4 		$17.8M Buy
1,526,994
+1,059,751
+227% +$16.5M 0.06% 385
2024
Q3 		$9.6M Buy
467,243
+14,795
+3% +$341K 0.03% 597
2024
Q2 		$10.1M Sell
452,448
-343,066
-43% -$8.17M 0.04% 553
2024
Q1 		$21.9M Buy
795,514
+762,258
+2,292% +$21.2M 0.08% 310
2023
Q4 		$1.01M Buy
+33,256
New +$956K ﹤0.01% 942
2023
Q3 		– Sell
-72,443
Closed -$2.95M – 1540
2023
Q2 		$2.95M Sell
72,443
-10,996
-13% -$446K 0.01% 863
2023
Q1 		$3.11M Buy
83,439
+61,201
+275% +$2.4M 0.02% 833
2022
Q4 		$776K Buy
+22,238
New +$1.06M ﹤0.01% 1190
2022
Q3 		– Sell
-99,379
Closed -$5.14M – 1557
2022
Q2 		$5.14M Buy
99,379
+29,871
+43% +$1.52M 0.03% 665
2022
Q1 		$5.05M Buy
69,508
+19,023
+38% +$1.61M 0.03% 632
2021
Q4 		$5.97M Sell
50,485
-177,536
-78% -$22.2M 0.03% 652
2021
Q3 		$30.6M Buy
228,021
+124,418
+120% +$18.8M 0.2% 114
2021
Q2 		$16.8M Buy
+103,603
New +$8.07M 0.12% 228
2021
Q1 		– Sell
-4,868
Closed -$265K – 1572
2020
Q4 		$265K Sell
4,868
-20,572
-81% -$747K ﹤0.01% 1239
2020
Q3 		$506K Buy
+25,440
New +$530K ﹤0.01% 1086
2020
Q1 		– Sell
-20,382
Closed -$299K – 1300
2019
Q4 		$299K Buy
+20,382
New +$284K 0.01% 931
2019
Q3 		– Sell
-32,916
Closed -$539K – 1176
2019
Q2 		$539K Buy
+32,916
New +$517K 0.01% 550

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Voloridge Investment Management's NTLA Position: Q2 2026 in Review

Voloridge Investment Management increased its Intellia Therapeutics (NTLA) stake by 28% in Q2 2026, buying an estimated $6.37M and bringing the position to 2,066,356 shares worth $35M. The position accounts for 0.15% of the portfolio, ranked #220.

Voloridge Investment Management first reported a position in NTLA in Q2 2019 and has held it in 23 quarters since. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Voloridge Investment Management held 2,066,356 shares of Intellia Therapeutics worth $35M as of Q2 2026.
  • Voloridge Investment Management bought 454,822 Intellia Therapeutics shares in Q2 2026, an estimated $6.37M.
  • Intellia Therapeutics made up 0.15% of Voloridge Investment Management's portfolio in Q2 2026, its #220 holding.
  • Voloridge Investment Management first reported a position in Intellia Therapeutics in Q2 2019 and has held it in 23 quarters since.
  • 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Voloridge Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.